The Cooper Companies, Inc. (COO) Stock Analysis - January 2026

Company Overview

The Cooper Companies, Inc., headquartered in San Ramon, California, is a prominent player in the Healthcare sector, specifically within the Medical Instruments & Supplies industry. Founded in 1958, the company operates primarily through two segments--CooperVision and CooperSurgical. CooperVision specializes in contact lenses designed to meet various vision challenges, while CooperSurgical focuses on family and women's healthcare, offering products related to fertility, contraception, and medical devices. With a robust total revenue of approximately $4.09 billion, Cooper Companies is well-positioned to leverage ongoing trends in medical innovation and a growing demand for healthcare solutions.

The company predominantly sells its products to healthcare professionals, clinics, and authorized resellers, establishing a diverse clientele that enhances its industry position. As of the latest stock information, Cooper Companies has a target high price of $100. This suggests strong growth potential, driven by stable revenue streams and significant operational capability.

52-Week Price Performance Analysis

52-Week Price Performance Chart

Technical Overview

The 52-week price chart for The Cooper Companies, Inc. (COO) reveals a volatile yet increasingly bullish trajectory, characterized by significant price fluctuations throughout the year. Initially, the stock experienced a notable decline from a high of $100.24 in January to a yearly low of $61.78 in June, indicative of a bearish trend influenced by selling pressure. This phase was largely driven by market conditions and sector-specific challenges, reflected in lower highs and lower lows.

As the year progressed into the final months, a distinct recovery phase emerged. Post-October, COO successfully broke through the downward trend with evident higher highs and higher lows, indicating a shift in market sentiment towards bullishness. The current stock price of $82.34 sits comfortably between its 52-week high and low, demonstrating resilience and a capacity to recover.

Support and Resistance Levels

• Support Level: The $70 mark has shown significant support, having been tested multiple times around June and September. This level is critical for investors as it indicates a floor price where the stock has historically found buying interest.
• Resistance Level: Conversely, the $90 mark serves as a prominent resistance level, previously hindering upward movement. The stock has recently approached the $82 level, which may act as a temporary resistance point before further consolidation.

Recent bullish momentum has led analysts to focus on the 50-day moving average, currently situated at $76.01. The crossover event observed, where the stock price moves above the moving average, signifies potential further upside if supported by continued buying interest. If CO can break past $82, it could indicate an upward shift toward retesting the $90 resistance.

Financial Performance and Metrics

The financial performance of The Cooper Companies is substantial, showcasing its operational efficiency and robust profitability. Highlights of key financial metrics include:

• Total Revenue: Approximately $4.09 billion, marking strong operational stability in a competitive industry.
• EBITDA: Stands at $1.06 billion, underscoring the company's ability to generate cash and profitability.
• Share Data: With a total of 195,978,026 shares outstanding, and approximately 7,370,102 shares shorted, the short percent of float stands at 0.039. This indicates a low level of skepticism among investors regarding COO's long-term outlook.
• Current Stock Price: As of December 31, 2025, the stock price is $82.34, which not only exceeds the 50-day moving average but also indicates potential for further growth.

Recent News and Developments

Recent developments at The Cooper Companies, Inc. indicate heightened investor interest and potential for strategic growth:

1. Strategic Review Announcement: The company initiated a comprehensive strategic review to explore options such as partnerships, joint ventures, and possible mergers. This aligns with efforts to enhance long-term shareholder value and stakeholder engagement.

2. Fiscal Fourth-Quarter Results: The announcement of fiscal fourth-quarter results marked a positive surprise for analysts, with revenue reaching $1.07 billion, reflecting a 5% year-over-year increase. Notably, non-GAAP diluted earnings per share improved by 11%, rising to $1.15.

3. Analyst Rating Adjustments: Following the strategic review announcement, several investment banks, including Baird and Needham, raised their price targets for COO, with Baird setting a new target of $98 and Needham at $100.

4. Activist Investor Engagement: Activist investor Jana Partners acquired a stake in the company, advocating for strategic changes, including a potential merger of CooperVision with Bausch + Lomb. This movement has created buzz among investors and further uplifted COO's stock price.

Market Sentiment and Analyst Recommendations

Market sentiment surrounding The Cooper Companies has shifted positively, bolstered by strategic developments and robust quarterly performance. Despite the lack of a formal recommendation key, analysts have been closely monitoring COO's ascent.

• Analyst Consensus: There are 16 analyst opinions contributing to the analysis. The average target price is currently identified at $90.50, with a median target slightly higher at $92.50. While this indicates potential price appreciation, the absence of consensus implies a cautious stance toward volatility.

• Price Target Variability: Analysts broadly expect price movement between a target high of $100.00 and a target low of $71.00, suggesting a degree of uncertainty in stock performance but also acknowledging the inherent value in COO as a healthcare entity.

In summary, the outlook for The Cooper Companies, Inc. suggests a careful balance of risk and opportunity. With promising financial metrics, strategic reviews potentially uplifting the stock, and favorable analytics, the company could be a valuable addition to an investor's portfolio--provided they remain cognizant of possible market fluctuations.

In conclusion, as we head into 2026, The Cooper Companies present a compelling case for investment consideration amid a landscape governed by healthcare innovation and increasing consumer demand.